Hikma Pharmaceuticals PLC (LON:HIK)
1,402.50
+80.50 (6.09%)
Apr 23, 2026, 4:35 PM GMT
Hikma Pharmaceuticals Revenue
In the year 2025, Hikma Pharmaceuticals had annual revenue of $3.35B USD with 7.10% growth. Hikma Pharmaceuticals had revenue of $1.69B in the half year ending December 31, 2025, with 16.78% growth.
Revenue
$3.35B
Revenue Growth
+7.10%
P/S Ratio
1.22
Revenue / Employee
$356.28K
Employees
9,400
Market Cap
3.03B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.35B | 222.00M | 7.10% |
| Dec 31, 2024 | 3.13B | 252.00M | 8.77% |
| Dec 31, 2023 | 2.88B | 358.00M | 14.22% |
| Dec 31, 2022 | 2.52B | -36.00M | -1.41% |
| Dec 31, 2021 | 2.55B | 212.00M | 9.06% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Haleon | 11.03B |
| HUTCHMED (China) | 407.54M |
| ECO Animal Health Group | 85.81M |
| Allergy Therapeutics | 57.29M |
| Shield Therapeutics | 36.93M |
| Venture Life Group | 35.17M |
| Provexis | 871.27K |
| Chill Brands Group | 370.50K |
Hikma Pharmaceuticals News
- 21 hours ago - UK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran war - Reuters
- 4 months ago - Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US - PRNewsWire
- 9 months ago - Hikma Pharmaceuticals tumbles after injectables margin outlook cut - Reuters
- 10 months ago - Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US - PRNewsWire
- 10 months ago - Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines - PRNewsWire
- 11 months ago - Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection - PRNewsWire
- 11 months ago - Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection - PRNewsWire
- 1 year ago - Hikma acquires Novugen's FDA-approved ANDA for trametinib - PRNewsWire